Brokerages Set Neurocrine Biosciences, Inc. (NASDAQ:NBIX) PT at $139.25

Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) have been given an average rating of “Moderate Buy” by the twenty-two brokerages that are covering the firm, MarketBeat.com reports. Six analysts have rated the stock with a hold recommendation and sixteen have assigned a buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $139.67.

A number of analysts recently issued reports on NBIX shares. JPMorgan Chase & Co. increased their target price on Neurocrine Biosciences from $148.00 to $158.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 20th. The Goldman Sachs Group raised their price target on Neurocrine Biosciences from $134.00 to $153.00 and gave the company a “buy” rating in a research note on Thursday, January 25th. Barclays upped their price objective on Neurocrine Biosciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 23rd. StockNews.com upgraded shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 8th. Finally, Citigroup cut their price target on shares of Neurocrine Biosciences from $141.00 to $140.00 and set a “neutral” rating for the company in a research note on Thursday, February 8th.

Neurocrine Biosciences Price Performance

Shares of NBIX stock opened at $133.23 on Monday. The firm has a market cap of $13.26 billion, a price-to-earnings ratio of 55.05 and a beta of 0.25. Neurocrine Biosciences has a one year low of $89.04 and a one year high of $148.37. The stock’s fifty day simple moving average is $136.19 and its 200 day simple moving average is $126.81.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Wednesday, February 7th. The company reported $1.44 EPS for the quarter, beating the consensus estimate of $1.13 by $0.31. The company had revenue of $515.20 million during the quarter, compared to analysts’ expectations of $518.52 million. Neurocrine Biosciences had a return on equity of 12.85% and a net margin of 13.23%. The business’s revenue for the quarter was up 25.0% on a year-over-year basis. During the same period last year, the firm earned $0.88 EPS. On average, research analysts anticipate that Neurocrine Biosciences will post 4.84 earnings per share for the current year.

Insider Transactions at Neurocrine Biosciences

In related news, insider Eric Benevich sold 19,818 shares of the company’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $133.36, for a total value of $2,642,928.48. Following the transaction, the insider now directly owns 40,778 shares in the company, valued at $5,438,154.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Neurocrine Biosciences news, insider Eric Benevich sold 19,818 shares of the firm’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $133.36, for a total transaction of $2,642,928.48. Following the transaction, the insider now owns 40,778 shares in the company, valued at approximately $5,438,154.08. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director George J. Morrow sold 40,000 shares of the company’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $139.42, for a total transaction of $5,576,800.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 196,994 shares of company stock valued at $27,205,009. 4.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Neurocrine Biosciences

A number of institutional investors have recently modified their holdings of the business. Hennion & Walsh Asset Management Inc. lifted its stake in shares of Neurocrine Biosciences by 14.3% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 6,805 shares of the company’s stock valued at $939,000 after acquiring an additional 853 shares during the last quarter. Toth Financial Advisory Corp boosted its position in Neurocrine Biosciences by 34.6% during the 1st quarter. Toth Financial Advisory Corp now owns 5,500 shares of the company’s stock worth $759,000 after buying an additional 1,413 shares during the period. Chesley Taft & Associates LLC bought a new stake in shares of Neurocrine Biosciences in the first quarter worth $1,034,000. Wealth Enhancement Advisory Services LLC grew its position in shares of Neurocrine Biosciences by 48.5% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 4,744 shares of the company’s stock valued at $654,000 after buying an additional 1,550 shares during the last quarter. Finally, Park Avenue Securities LLC boosted its holdings in Neurocrine Biosciences by 1.1% in the first quarter. Park Avenue Securities LLC now owns 9,570 shares of the company’s stock valued at $1,320,000 after acquiring an additional 101 shares during the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.